Public Market Listing
BAYN Xetra
Xetra primary exchange listing
External market data link · No third-party exchange redistribution
Assets (21 total) 21 Total Assets
12 Approved
3 Phase 3 / Filed
6 Phase 1–2 / Early
19 Diseases
Disease: All diseases (21) Non-Small Cell Lung Cancer (4) Heart Failure (3) Chronic Kidney Disease (3) Type 2 Diabetes (2) Transthyretin-Mediated Amyloidosis (1) Hypertrophic Cardiomyopathy (1) Age-Related Macular Degeneration (1) Diabetic Macular Edema (1) Multiple Sclerosis (1) Solid Tumors (1) Subarachnoid Hemorrhage (1) Hepatocellular Carcinoma (1) Colorectal Cancer (1) Gastrointestinal Stromal Tumor (1) Pulmonary Arterial Hypertension (1) Parkinson's Disease (1) Pulmonary Hypertension Associated with Interstitial Lung Disease (1) Hypertension (1) Atherosclerotic Cardiovascular Disease (1)
Stage: All stages (21) Approved / Phase 4 (12) Phase 3 / Filed (3) Phase 2 Phase 1 / Preclinical
Quick filter: All (21) Non-Small Cell Lung Cancer (4) Heart Failure (3) Chronic Kidney Disease (3) Type 2 Diabetes (2) Transthyretin-Mediated Amyloidosis (1)
Showing 21 of 21 assets
Asset ↕ Stage ↓ Target & Modality Disease / Indication ↕ Approved Alpha-glucosidase Small molecule
Approved Transthyretin (TTR) Small molecule
Transthyretin-Mediated Amyloidosis
Transthyretin Amyloidosis with Cardiomyopathy Approved Cardiac myosin (inhibitor) Small molecule
Hypertrophic Cardiomyopathy
Approved VEGF-A · VEGF-A / VEGF-B / Placental Growth Factor (PlGF) Protein / enzyme therapeutic
Age-Related Macular Degeneration Diabetic Macular Edema
Wet Age-Related Macular Degeneration Approved Mineralocorticoid receptor Small molecule
Heart Failure Chronic Kidney Disease
Approved Interferon beta receptor (type I IFN signaling) · Type I interferon receptor Biologic (subtype unspecified)
Approved TRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions) Small molecule
Non-Small Cell Lung Cancer Solid Tumors
Approved L-type calcium channels (Cav1.2) Small molecule
Approved Multi-kinase inhibitor (VEGFR/PDGFR/KIT) Small molecule
Hepatocellular Carcinoma Colorectal Cancer Gastrointestinal Stromal Tumor
Metastatic Colorectal Cancer, Advanced Metastatic Colorectal Cancer Approved Soluble guanylate cyclase Small molecule
Pulmonary Arterial Hypertension
Approved EGFR/HER2 Small molecule
Non-Small Cell Lung Cancer
Approved Soluble guanylate cyclase Small molecule
US approval withdrawn Alpha-glucosidase Small molecule
Phase 3 Midbrain dopaminergic neurons Cell therapy
Phase 3 HIF prolyl hydroxylase (HIF-PH1/2/3) Small molecule
Show all 21 assets (6 more) ↓ Discontinued programmes (5) Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events (18 total) Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link . The calendar updates when a registry date moves.
2026 (1) December 2026 (1) Mosliciguat Phase 2 Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis Est. primary completion 2026-12 ·
NCT07333183 ·
CT.gov ↗ What to watch
2027 (2) April 2027 (1) October 2027 (1) Sevabertinib · Hyrnuo Phase 3 Advanced Non-small Cell Lung Cancer, HER2 Mutation Est. primary completion 2027-10-28 ·
NCT06452277 ·
CT.gov ↗ What to watch
2028 (5) April 2028 (2) Acoramidis · Attruby Phase 3 Amyloid Cardiomyopathy, Transthyretin-Related Est. primary completion 2028-04-15 ·
NCT04988386 ·
CT.gov ↗ What to watch
Regorafenib Phase 2 Solid Malignant Tumors Est. primary completion 2028-04-27 ·
NCT06246643 ·
CT.gov ↗ What to watch
August 2028 (1) Finerenone · Kerendia Phase 3 Chronic Kidney Disease, Proteinuria, Children Est. primary completion 2028-08-07 ·
NCT05457283 ·
CT.gov ↗ What to watch
October 2028 (1) December 2028 (1) Sevabertinib · Hyrnuo Phase 1/2 Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation Est. primary completion 2028-12-01 ·
NCT05099172 ·
CT.gov ↗ What to watch
2029 (6) January 2029 (1) Mosliciguat Phase 3 Pulmonary Hypertension, Interstitial Lung Disease, Vascular Diseases, Cardiovascular Diseases, Fibrosis Est. primary completion 2029-01-28 ·
NCT07816185 ·
CT.gov ↗ What to watch
February 2029 (1) March 2029 (1) Aficamten · Myqorzo Phase 2/3 Symptomatic Hypertrophic Cardiomyopathy (HCM) Est. primary completion 2029-03 ·
NCT04848506 ·
CT.gov ↗ What to watch
June 2029 (1) BAY 3713372 Phase 1/2 MTAP-deleted Solid Tumors Est. primary completion 2029-06-18 ·
NCT06914128 ·
CT.gov ↗ What to watch
August 2029 (1) Vericiguat · Verquvo Phase 2/3 Heart Failure, Left Ventricular Systolic Dysfunction Est. primary completion 2029-08-20 ·
NCT05714085 ·
CT.gov ↗ What to watch
November 2029 (1) Finerenone · Kerendia Phase 3 Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric) Est. primary completion 2029-11-30 ·
NCT07188805 ·
CT.gov ↗ What to watch
2030 (2) January 2030 (1) Aficamten · Myqorzo Phase 2/3 Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy Est. primary completion 2030-01 ·
NCT06412666 ·
CT.gov ↗ What to watch
December 2030 (1) Finerenone · Kerendia Phase 3 Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric) Est. primary completion 2030-12-30 ·
NCT07192952 ·
CT.gov ↗ What to watch
2031 (1) October 2031 (1) Acoramidis · Attruby Phase 3 Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies, Heart Diseases, Polyneuropathies Est. primary completion 2031-10 ·
NCT06563895 ·
CT.gov ↗ What to watch
2037 (1) November 2037 (1) Acoramidis · Attruby Phase 3 Amyloidosis in Transthyretin (TTR), Amyloidosis, Familial, Amyloid Cardiomyopathy, Amyloid Cardiomyopathy, Transthyretin-Related … Est. primary completion 2037-11 ·
NCT07116473 ·
CT.gov ↗ What to watch
See the full readout calendar ↗
Regulatory and conference events (15) Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
8 October 2026 Filing accepted Finerenone FDA accepts Bayer's sNDA for finerenone (Kerendia) in adults with chronic kidney disease without diabetes (announced 2026-10-08) 17 September 2026 Approval Finerenone FDA approves Kerendia for CKD associated with type 1 diabetes 9 September 2026 Approval Sevabertinib FDA grants accelerated approval to Hyrnuo as a first-line treatment 8 September 2026 Topline result Mosliciguat Phase 2 PHocus of inhaled mosliciguat in PH-ILD met its primary endpoint 5 August 2026 Withdrawal Iloprost FDA withdraws approval of NDA 021779 (Federal Register 2026-13616) August 2026 Approval Riociguat FDA updates Boxed Warning on Adempas (NDA204819) 5 May 2026 Topline result Aficamten ACACIA-HCM Phase 3 of aficamten in non-obstructive HCM met both dual primary endpoints May 2026 Priority review Finerenone FDA grants Priority Review for finerenone in CKD with type 1 diabetes 2 April 2026 Approval Aflibercept FDA approves EYLEA HD dosing intervals up to every 20 weeks April 2026 FDA action date Aflibercept FDA target action date for EYLEA HD prefilled syringe 16 March 2026 Topline result Finerenone FIND-CKD Phase III meets primary endpoint 16 January 2026 Approval Aflibercept Eylea 8 mg approved in the EU for macular edema following RVO The 12 most recent of 15 past events are shown.
Financial reports Quarterly & interim (1)
Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2026-Q1 $15.7B $1.7B $6.6B — report ↗
Annual history (5 years)
Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2025-FY $51.7B $6.5B $7.8B $4.1B report ↗
Bayer reported revenue of $51,661.2M, up 2.4% YoY, R&D spend of $6,539.41M, down 2.7% YoY, cash and equivalents of $7,842.83M, and a quarterly net burn of $4,103.42M for fiscal year 2025.
Figures only: this period's report disclosed no narrative text
View 4 more years Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2024-FY $50.4B $6.7B $6.4B $2.8B report ↗ 2023-FY $51.5B $5.8B — $3.2B report ↗ 2022-FY $53.5B $6.9B — — report ↗ 2021-FY $52.2B $6.4B — — report ↗